Latest Weight-Loss Drug , Faces Shortages .<br />The United States Food and Drug Administration <br />(FDA) says that high demand has left the latest <br />weight-loss drug, Zepbound, in short supply.<br />'Newsweek' reports that the Eli Lilly product<br />is expected to experience limited availability <br />through Q2 of 2024 as surging demand has <br />outpaced the manufacturer's expectations.<br />We have experienced <br />an unparalleled surge in <br />demand for our type 2 <br />diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.<br />We recognize this situation may <br />cause a disruption in peoples' <br />treatment regimens and are <br />working with purpose and <br />urgency to help meet <br />the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.<br />The FDA said that Novo Nordisk's weight-loss <br />drug, Wegovy, is also experiencing a <br />widespread supply shortage with no end <br />in sight for the drug's limited availability.<br />By the year 2030, 'Newsweek' reports <br />that the weight-loss drug market is <br />expected to grow to about $100 billion.<br />We expect our investments <br />in manufacturing and supply <br />capacity to progressively increase <br />production of our medicines <br />throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.<br />Over the past year, manufacturer Eli Lilly <br />has already seen share prices rise over 102%.<br />The company has announced plans <br />to expand operations to meet increased <br />demand for its incretin products which are <br />used in the firm's diabetes treatments. .<br />Incretin mimics gut hormones <br />that regulate blood sugar <br />while also suppressing appetite
